These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12142388)

  • 21. Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study.
    Birgisson H; Nielsen HJ; Christensen IJ; Glimelius B; Brünner N
    Eur J Cancer; 2010 Dec; 46(18):3323-31. PubMed ID: 20619633
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals.
    Nielsen HJ; Brünner N; Jorgensen LN; Olsen J; Rahr HB; Thygesen K; Hoyer U; Laurberg S; Stieber P; Blankenstein MA; Davis G; Dowell BL; Christensen IJ; ;
    Scand J Gastroenterol; 2011 Jan; 46(1):60-9. PubMed ID: 20799911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
    Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
    Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levels of tissue inhibitor of metalloproteinases 1 in plasma and urine from patients with bladder cancer.
    Holten-Andersen MN; Brünner N; Nielsen HJ; Christensen IJ; Sørensen NM; Rasmussen AS; Primdahl H; Orntoft T
    Int J Biol Markers; 2006; 21(1):6-11. PubMed ID: 16711508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer.
    Böckelman C; Beilmann-Lehtonen I; Kaprio T; Koskensalo S; Tervahartiala T; Mustonen H; Stenman UH; Sorsa T; Haglund C
    BMC Cancer; 2018 Jun; 18(1):679. PubMed ID: 29929486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of psoriasis treatment on plasma concentrations of metalloproteinase-1 and tissue inhibitor of metalloproteinases-1.
    Flisiak I; Myśliwiec H; Chodynicka B
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):418-21. PubMed ID: 15987285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma.
    Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Noguchi Y; Takanashi Y
    Br J Surg; 2001 Dec; 88(12):1596-601. PubMed ID: 11736971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigating the biomarker potential of glycoproteins using comparative glycoprofiling - application to tissue inhibitor of metalloproteinases-1.
    Thaysen-Andersen M; Thøgersen IB; Lademann U; Offenberg H; Giessing AM; Enghild JJ; Nielsen HJ; Brünner N; Højrup P
    Biochim Biophys Acta; 2008 Mar; 1784(3):455-63. PubMed ID: 18206988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levels of tissue inhibitor of metalloproteinases-1 in blood transfusion components.
    Holten-Andersen MN; Brunner N; Christensen IJ; Jensen V; Nielsen HJ
    Scand J Clin Lab Invest; 2002; 62(3):223-30. PubMed ID: 12088341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased plasma matrix metalloproteinase-2 (MMP-2), tissue inhibitor of proteinase-1 (TIMP-1), TIMP-2, and urine MMP-2 concentrations correlate with proteinuria in renal transplant recipients.
    Mazanowska O; Zabińska M; Kościelska-Kasprzak K; Kamińska D; Krajewska M; Banasik M; Madziarska K; Zmonarski SC; Chudoba P; Biecek P; Boratyńska M; Klinger M
    Transplant Proc; 2014 Oct; 46(8):2636-9. PubMed ID: 25380883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma tissue inhibitor of metalloproteinases-1 as a biological marker? Pre-analytical considerations.
    Lomholt AF; Frederiksen CB; Christensen IJ; Brünner N; Nielsen HJ
    Clin Chim Acta; 2007 May; 380(1-2):128-32. PubMed ID: 17328880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer.
    Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Imada T; Noguchi Y
    Anticancer Res; 2004; 24(3b):2101-5. PubMed ID: 15274408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue inhibitor of metalloproteinases-1 as a biological marker in colorectal cancer: influence of smoking on plasma levels?
    Rasmussen L; Ladelund S; Brünner N; Jørgensen LN; Nielsen HJ; Sørensen LT
    Int J Biol Markers; 2013 Jun; 28(2):226-30. PubMed ID: 23592002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
    Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
    Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
    Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
    Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Tissue inhibitor of metalloproteinase-1 (TIMP-1) in colorectal cancer: correlation with clinico-morphological factors].
    Korotkova EA; Gershteĭn ES; Prorokov VV; Kushlinskiĭ NE
    Vopr Onkol; 2009; 55(2):171-6. PubMed ID: 19514370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma levels of tissue inhibitor of matrix metalloproteinase-1 correlate with diagnosis and prognosis of glioma patients.
    Lin Y; Wang JF; Gao GZ; Zhang GZ; Wang FL; Wang YJ
    Chin Med J (Engl); 2013 Nov; 126(22):4295-300. PubMed ID: 24238516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma transforming growth factor beta1, metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 in acute viral hepatitis type B.
    Flisiak R; Jaroszewicz J; Lapiński TW; Flisiak I; Rogalska M; Prokopowicz D
    Regul Pept; 2005 Nov; 131(1-3):54-8. PubMed ID: 16081167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer.
    Schrohl AS; Mueller V; Christensen IJ; Pantel K; Thomssen C; Bruenner N
    Tumour Biol; 2008; 29(3):181-7. PubMed ID: 18645261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of blood sampling procedure on plasma concentrations of matrix metalloproteinases and their tissue inhibitors.
    Rossignol P; Cambillau M; Bissery A; Mouradian D; Benetos A; Michel JB; Plouin PF; Chatellier G; Jacob MP
    Clin Exp Pharmacol Physiol; 2008 Apr; 35(4):464-9. PubMed ID: 18307742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.